All divers require a platform.
Accordingly, Dr. Richard Gordon, an Associate Professor from Queensland, Australia will do a deep dive on the anti-Parkinsonian activity of EpicentRx lead small molecule, RRx-001 (nibrozetone), during a one-hour platform presentation at the 2024 International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Philadelphia, Pennsylvania.
RRx-001 is a CNS-active agent that binds to and inhibits the NLRP3 inflammasome, which initiates and perpetuates inflammation, and stimulates the Nrf2 antioxidant transcription factor.
Because the MDS annual meeting is chockablock with pharmaceutical companies, Dr. Gordon and EpicentRx will present their groundbreaking research on RRx-001 to a highly receptive audience. The title of the presentation is “Validating the clinical stage NLRP3 inflammasome inhibitor RRx-001 (nibrozetone) as a disease-modifying therapeutic for Parkinson’s disease.”
It is scheduled to take place on Saturday September 28 from 1:30-2:30 pm EST.
That is what we call a meeting of the minds or a meeting of da minds (MDS) on RRx-001.